Document is current
Any future updates will be listed below
-
Authors
Marogi, Jacob G.
Murphy, Coleen T. https://orcid.org/0000-0002-8257-984X
Myhrvold, Cameron https://orcid.org/0000-0002-8971-184X
Gitai, Zemer https://orcid.org/0000-0002-3280-6178
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R01AT011963-01, R21AI168808-01)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | Centers for Disease Control and Prevention (75D30122C15113)
- License Information
-
More Information
Article History
Received: 25 June 2024
Accepted: 29 August 2024
First Online: 10 September 2024
Competing interests
: Z.G. has a competing interest as founder of ArrePath, Inc. C.M. is a cofounder of Carver Biosciences, a startup company developing Cas13-based antivirals, and holds equity in Carver Biosciences. The remaining authors declare no competing interests.
